Drug intelligence / Profile preview

ketotifen + montelukast

Development stage: Unknown
Lead developer: Sandoz
Modality: Small Molecules
Administration: Oral, Topical

Overview

Ketotifen + montelukast is a combination medication used primarily for respiratory conditions. Montelukast is a leukotriene receptor antagonist that prevents leukotrienes from binding to receptors in airways, reducing inflammation, mucus secretion, and airway hyperresponsiveness. Ketotifen is a histamine H1 receptor antagonist and mast cell stabilizer that inhibits the release of inflammatory mediators. Together, they provide complementary mechanisms to treat asthma, allergic rhinitis, and chronic obstructive pulmonary disease (COPD), particularly in cases with airway hyperresponsiveness.

Other names: montelukast sodium + ketotifen fumarate

Targets

CYSLTR1 (Cysteinyl-leukotriene type 1 receptor)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on ketotifen + montelukast.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ketotifen + montelukast.

Explore the full profile